OrbusNeich Medical Group Holdings Ltd
HKEX:6929
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
OrbusNeich Medical Group Holdings Ltd
Change in Working Capital
OrbusNeich Medical Group Holdings Ltd
Change in Working Capital Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Change in Working Capital | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
O
|
OrbusNeich Medical Group Holdings Ltd
HKEX:6929
|
Change in Working Capital
-$28.4m
|
CAGR 3-Years
-64%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
H
|
Huakang Biomedical Holdings Co Ltd
HKEX:8622
|
Change in Working Capital
-¥1.7m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-1%
|
CAGR 10-Years
N/A
|
|
|
K
|
Kaisa Health Group Holdings Ltd
HKEX:876
|
Change in Working Capital
-HK$22m
|
CAGR 3-Years
10%
|
CAGR 5-Years
0%
|
CAGR 10-Years
N/A
|
|
|
K
|
Kelfred Holdings Ltd
HKEX:1134
|
Change in Working Capital
HK$25.6m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
30%
|
CAGR 10-Years
N/A
|
|
|
Arts Optical International Holdings Ltd
HKEX:1120
|
Change in Working Capital
HK$23.4m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-23%
|
CAGR 10-Years
-6%
|
|
OrbusNeich Medical Group Holdings Ltd
Glance View
OrbusNeich Medical Group Holdings Ltd. operates as an investment holding company. The company employs 880 full-time employees The company went IPO on 2022-12-23. The firm is engaged in the design, development, manufacture, distribution and sale of interventional medical devices for the treatment of coronary heart disease and peripheral vascular diseases. The firm's main products include percutaneous coronary intervention (PCI) and percutaneous transluminal angioplasty (PTA) balloons. In addition, the Company's products also include semi-compliant balloons and scoring balloons for pre-dilatation and lesion preparation, coronary stents for implantation, non-compliant balloons for post-dilatation and specialty catheters. The firm mainly conducts its businesses in domestic and overseas markets.
See Also
What is OrbusNeich Medical Group Holdings Ltd's Change in Working Capital?
Change in Working Capital
-28.4m
USD
Based on the financial report for Dec 31, 2025, OrbusNeich Medical Group Holdings Ltd's Change in Working Capital amounts to -28.4m USD.
What is OrbusNeich Medical Group Holdings Ltd's Change in Working Capital growth rate?
Change in Working Capital CAGR 3Y
-64%
Over the last year, the Change in Working Capital growth was 4%. The average annual Change in Working Capital growth rates for OrbusNeich Medical Group Holdings Ltd have been -64% over the past three years .
